Laboratory Products
Microinjection-Ready Cas9 Accelerate Ribonucleoprotein Introduced
Mar 22 2016
Horizon Discovery Group plc have announced the introduction of microinjection-ready Cas9 Accelerate Ribonucleoprotein (RNP).
The new Cas9 Accelerate RNP adds to Horizon’s existing collection of microinjection ready reagents for gene editing of animal models. Cas9 Accelerate RNP maximises gene editing efficiency by enabling CRISPR reagents to sidestep the transcription and translation steps that traditional Cas9 plasmid and mRNA formats must complete before being activated, thereby maximising gene editing efficiency and lowering the risk of off-target effects.
Dr Kevin Gamber, Director, Marketing and Business Development, Horizon Discovery Group, commented: “Horizon’s collection of microinjection ready CRISPR reagents represent the most expertly-designed, rigorously validated, fast-acting and efficient gene editing tools available. Using the new Cas9 Accelerate RNP, gene editing can now be performed more quickly and efficiently.”
Horizon Discovery uses the same optimised sgRNA and Cas9 Accelerate RNP pre-mixed formulation for its in-house, custom animal model generation service.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland
Analytica Anacon India & IndiaLabExpo
Apr 15 2024 Mumbai, India
Apr 16 2024 Moscow, Russia